Introduction
The use of orthogonal assays (e.g., Sanger sequencing) to confirm variants identified by next-generation sequencing (NGS) is standard practice in many laboratories to reduce the risk of delivering false-positive (FP) results. Clinical NGS tests can inform significant medical decisions [1, 2] , and thus confirmation is recommended by medical practice guidelines [3, 4] although the details are generally left up to the laboratory [3, 5] . Because the methods used in clinical NGS often emphasize sensitivity (to avoid missing clinically important variants), FP rates can be elevated compared with those in research NGS [6] . Moreover, pathogenic variants are often technically challenging (e.g., many are located within repetitive sequences or segmental duplications), which can further increase FP rates [7] [8] [9] . Confirmation assays have a monetary cost, however, and can increase the time needed to deliver results, a critical factor in many clinical situations.
Published studies examining this issue have concluded that confirmation of the highest-quality NGS calls may not always be necessary [10] [11] [12] [13] . Some of these studies [10, 12] propose specific criteria to separate high-confidence true-positive (TP) variant calls from those that are possibly but not confidently true ( Figure 1 ). These criteria differ from those used in filtering, the separate process of removing calls confidently believed to be false or unsupportable. The remaining intermediate-confidence calls are those that indeed benefit from confirmatory assays, manual data review, or both to determine which are TPs and which are FPs. Unfortunately, these prior studies are generally small, in some cases proposing quality thresholds using only a single example FP (Table 1 , Figure 1 ). At first glance, the presence of few FPs may seem reassuring.
However, this leads to significant limitations in these studies. First, because their statistical power to characterize the FP population is limited, these studies do not address the question of whether future FPs are likely to resemble the few observed in PRE-PRINT 5/31/2018 the study. Quite possibly, additional FPs could be different and thus missed by the proposed criteria. Secondly, these studies use identical datasets for training and evaluating the proposed criteria, likely making the results subject to overfitting [14] .
Few of these prior studies provide statistical justifications for their proposed criteria.
Finally, these prior studies use data from individual laboratories and do not examine whether their methodologies could be generalized across settings.
We set out to examine the role of confirmation using a much larger set of variant calls than had been published previously. We combined five reference samples characterized by the Genome in a Bottle Consortium (GIAB) [15] [16] [17] with confirmatory data from over 80,000 clinical tests. Our methodology was applied in two clinical laboratories that use similar but not identical NGS methods. Like prior studies, we found it possible to identify high-confidence NGS calls that do not benefit from confirmation. However, we found that a battery of criteria was necessary to capture all FPs, in contrast with the one or two metrics used in prior studies. Indeed we found that the specific criteria proposed by prior studies would miss FPs in our, much larger, datasets. We also found that observations of a variant as a TP can say little about its chance of being an FP in a different run, which indicates that historical performance can be an ineffective quality metric. Approaches such as ours can be used by many laboratories to provide efficient, effective, and statistically justified criteria for prioritizing variant calls for confirmation.
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Methods
We compiled eight component datasets from two laboratories (Table 1) following the process illustrated in Figure 1 . Five GIAB specimens were used: NA12878, NA24385, NA24143, NA24149, and NA24631 (Coriell Institute, Camden, NJ) with reference data version 3.3.2 downloaded from www.genomeinabottle.org. Both laboratories' sequencing and bioinformatics methods have been described previously [8, 18, 19] . In brief, NGS was performed using Illumina (San Diego, CA) 2x150 base pair (bp) reads.
Seven (Lab 1) and three (Lab 2) custom hybridization-based targeting assays were used, each targeting the exons of 100-1000 genes. Average coverage in targeted regions was minimally 300x and typically 500-1000x or more depending on the assay and laboratory. Replicates of the GIAB samples were included.
Both laboratories used the Genome Analysis Toolkit (GATK) Haplotype Caller software [20, 21] , although there were many differences between the two laboratories' bioinformatics pipelines. Copy number and structural variants were excluded from this analysis. Variant filtering and manual review were performed according to each laboratory's clinically validated criteria, and variant calls that were filtered or manually removed were excluded from this analysis. Orthogonal confirmation of clinical NGS calls that passed manual review was performed using Sanger (Thermo Fisher, Waltham, MA) or Pacific Biosciences (Menlo Park, CA) sequencing. Multiple rounds of confirmation using different primers were performed as needed.
VCF (variant call format) files were annotated using the stratification BED (browser extensible data) files produced by the Global Alliance for Genomics and Health (GA4GH) benchmarking workgroup [22] (Supplemental Table 1 ). These files delineate genomic regions by technical complexity (e.g., repetitive sequences). These regions were padded by 10 bp on each side to ensure that all affected positions were appropriately annotated. The sample-specific GIAB "high-confidence" BED files were PRE-PRINT 5/31/2018 used to define regions (called GIAB-HC) where the reference calls were known to be highly accurate [17] . In patient specimens, the union of the five GIAB-HC files was used to determine regions that were considered GIAB-HC -i.e., if a region was considered high confidence in any of the five GIAB reference datasets, it was considered to be GIAB-HC in all patients. This approach prevents specific low-confidence variant calls in a particular GIAB specimen from inappropriately annotating that site as low confidence in general. Both laboratories defined clinical target regions to include, with rare exceptions, protein-coding exons plus immediate flanking sequences (10-20 bp on each side).
GIAB reference calls were used as confirmation data for variants uncovered in the GIAB specimens. Manual review was not performed for these calls, although analysis was restricted to the GIAB-HC regions. VCFeval [23] was used to compare our variant calls to the reference data and determine which calls were TPs and which were FPs.
VCFeval can match variant calls even when the same diploid sequence is represented in different ways, an important factor when comparing indels and complex variants [22, 23] . VCFeval also detects partial matches, e.g. zygosity errors (falsely calling a homozygous variant as heterozygous or vice versa) or sites at which one of two called alleles matches and one does not. These cases, collectively reported by VCFeval as "FP_CA", were considered FPs in our study. This study did not examine false negatives in detail.
Confidence intervals (CIs) were computed at 95% using the Jeffreys method. The
Wilson score method was also used for comparison in Figure 2 .
Results
Our data for this study included (a) almost 14,000 NGS variant calls subjected to confirmation during clinical testing, and (b) more than 184,000 calls with high-quality reference data from the GIAB samples (Table 1) . We observed a total of 1684 FPs within these datasets. We calculated the false discovery rate (FDR) of calls in each set, defined as the number of FPs divided by the number of FPs plus TPs. Note that FDR is 1 minus the analytic positive predictive value (aPPV), a metric recommended by the AMP/CAP guidelines, which consider aPPV preferable to computing specificity for multigene sequencing tests [24] . FDR varied considerably among our datasets owing to differences in the variant types, assay targets and methods. As expected, the FDR of indels was consistently higher than that of SNVs (single nucleotide variants). In the clinical data, Lab 2 applied less stringent filtering and manual review compared to Lab 1, which was reflected in the FDRs. For both laboratories, the indel FDR was particularly high in the GIAB datasets because (a) manual review had removed certain
FPs from the clinical datasets, and (b) off-target regions containing low-coverage, repetitive, and complex sequences were included in the GIAB data. Such regions are present but less common in clinical targets.
Analysis of individual quality metrics from Lab 1
We examined a variety of quality metrics to determine which were informative for identifying (or "flagging") FPs. We considered a variety of thresholds for each metric and computed the fraction of FPs and TPs flagged-these indicate the "value" and "cost," respectively, of using each metric and threshold. We also computed FDRs, compared with the baseline rate of 6.3%.
This observation was also true of our clinical dataset (Supplemental Figures 3-4G)
where 39% of FP SNVs and 2.9% of TPs had QUAL<800. These variants had a 3.6%
FDR compared with 0.16% overall -20-fold enrichment -although most low-quality calls were still TPs. There is little precision in these measurements, however, because the clinical dataset contained only 10 FP SNVs, and only four of those had QUAL<800. The genomic context of each variant was found to be informative (Supplemental Figures P, R) with important caveats. Repetitive sequences were enriched for FPs, although many TPs were also located in repeats, reflecting the fact that these sequences are highly polymorphic. Regions of poor mappability are generally not considered high-confidence (GIAB-HC), and we were thus unable to systematically examine error rates within these regions. Segmental duplications (segdups), were difficult to study for both similar and different reasons, including oversensitivity for marking regions as segdups using some methods.
Most other metrics proved to be informative for only a modest population of FPs. For example, neither read depth nor the quality-depth score (QD) performed well alone-indeed, some FPs had very high depth and QD (Supplemental Figures A-C, H ).
Strand bias metrics showed high efficiency, capturing very few TPs at useful thresholds (Supplemental Figures I-L) ; however, most FPs did not demonstrate significant strand bias, limiting the utility of these metrics. Indeed, we suspect that many more such variants exist, as our power to detect low FDRs is limited by the small number of GIAB specimens available.
Many (85%) of the GIAB variant calls used in this analysis were located in off-target regions. GIAB indel FDRs were similar on and off-target (5.3% vs. 6.4%, respectively) although SNV FDRs differed somewhat (0.04% vs. 0.17%). The GIAB analyses described above were repeated using only target regions for comparison (Supplemental Figures 13-14) producing generally consistent results albeit with far less confidence and power owing to the smaller dataset size.
Combining metrics
As no single metric proved adequate, we investigated whether combining metrics might work better. One precedent for this approach is the Mu et al. study [12] , in which the authors suggested that requiring depth>100 and AB between 40-60% will identify high confidence TPs that do not require confirmation. In our, much larger dataset this is not the case: More than 3% of FPs, both SNVs and indels, failed to be flagged as requiring confirmation using Mu's criteria. Nevertheless, we suspected that a larger battery of metrics might prove effective. 
Application of these methods to data from another laboratory
We examined whether a similar approach would work in the data from Lab 2, even though it used somewhat different NGS methods and bioinformatics. As of this analysis, Lab 2 had only sequenced one GIAB sample (NA12878) in replicate in addition to clinical data. FDRs in the GIAB data were roughly comparable between the two laboratories, which reflects specificity of the calling pipelines. The Lab 2 clinical
FDRs were however much higher than those of Lab 1 (see Table 1 ) owing to the different criteria used in filtering, manual review and selection of variants for confirmation.
We examined individual quality metrics (Supplemental Figures 5-8 ) observing similar patterns to those from Lab 1. Allele balance remained one of the most informative metrics, separating many FPs from TPs, but not all. Quality scores (QUAL and QD), read depth and and strand bias similarly identified some but not all FPs. Many indel FPs were located in or near repeats, although many TPs were also in these regions.
Het-alt variant calls and variants with other calls nearby were often erroneous. These themes were generally consistent between the GIAB data and the clinical dataset, and were also true in the GIAB data when we limited analysis to clinical target regions (Supplemental Figures 15-16 ). Similar to Lab 1, no single metric, such as QUAL, nor the AB/depth combination could flag all FPs in the full dataset without also flagging many TPs. As for Lab 1, variants with both FP and TP calls in different runs were observed.
We combined metrics using the same heuristic approach detailed above. We saw general consistency with the Lab 1 results, as depth, allele balance, QUAL score, strand bias, repeats, nearby variants, and other similar criteria were chosen by our algorithm (Supplemental Figures 11-12 ). There were differences in specific criteria and thresholds however (Supplemental Table 2 Another difference is that Clinical FPs, rather than GIAB FPs, comprised a large fraction of the Lab 2 dataset and played a significant role in determining both criteria and CIs (Table 1) . We do not consider this a problem although we note that clinical data can have significant biases, such as over-representation of specific relatively frequent pathogenic variants. Diversity of variants in a study such as ours is certainly advantageous. The unique variant count for Lab 2 will increase substantially, and the CIs will tighten when sequencing and analysis of the four additional GIAB samples is completed. Our results differ from those of prior studies in important ways. Neither quality score (as suggested by Strom et al. [10] ) nor the combination of allele balance and read depth (as suggested by Mu et al. [12] ) efficiently captured all of the FPs in our datasets even if we re-optimized thresholds. Although we acknowledge that criteria must be established independently for each NGS workflow-and indeed, workflows varied among these studies-we believe that this discrepancy results from the small datasets used in these prior studies, which may have left them underpowered and subject to overfitting (Table 1, Figure 2) . A study by Baudhuin et al. [11] reported no FPs, a seemingly excellent result. However, our data (Supplemental Figures 1-8 ) and other studies [6, 12] show that FPs are abundant at the threshold boundaries of most NGS quality indicators and that this marginal population contains a significant number of TPs as well. Thus, with current NGS methods, achieving high specificity with a single set of quality thresholds must sacrifice sensitivity. Indeed, a separate study showed that the specific methods used by Baudhuin had certain sensitivity limitations [7] .
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In our datasets, a battery of criteria, including read depth, strand bias, quality score, allele balance, genomic context, nearby calls, and other metrics were required to identify all FPs. This list closely follows the metrics recommended by the most recent AMP/CAP guidelines [24] . Many of these metrics are commonly used in variant filtering, albeit with different thresholds that emphasize sensitivity rather than specificity. In theory, a single quality score that captures all of these factors would be simpler to use than a battery of criteria. Unfortunately, we know of no current approach for computing such a score that will identify all FPs without capturing many TPs.
There were numerous benefits to using the large datasets we generated. These data not only provided a diverse set of FP calls that we could use in establishing criteria, but also offered ample data with which to establish separate training and test sets and identify outliers to minimize overfitting. Furthermore, we had adequate sample sizes for the computation of statistical measures of confidence, a crucial part of any laboratory validation study, albeit one that is not always used [24] . The statistical metric we used (CI lower bound given number of FPs) is rigorous but simple. More sophisticated approaches are feasible and ideal topics for future work. Prior studies report cumulative PPV, a metric which can be misleading in this context because FPs near the edge of quality thresholds can be diluted by a large number of very high confidence
TPs. Marginal error rates are far more informative for selecting thresholds and were extensively used in our study.
A key question is how large a dataset is adequate? Basic guidance can be found using the calculations described in recent guidelines [24, 25] . Whether demonstrating 95% at p = 0.05 is adequate is not a statistical question but a (Table 1) .
Obtaining a large number of FPs for study can be challenging, and we were careful not to do so in artificial and problematic ways. For example, FPs could be collected by simply lowering filtering thresholds. However, the resulting criteria might be good only at flagging clearly erroneous calls as opposed to defining the intermediate confidence set (Figure 1 ) for which confirmation matters most. Another approach would be to run many samples containing the same FP variants, either replicates or different patients with systematic errors. In this case, the resulting criteria might be good only for limited classes of FPs. To avoid these problems, we used the same filtering thresholds that we use in clinical practice and we considered both the number of unique variants and the number of variant calls when designing our study (Table 1) . Running the set of five GIAB specimens greatly increased the diversity of variants with confirmation data.
One might argue that our study artificially increased the number of FPs by including the off-target regions in the GIAB specimens. To the contrary, we consider it valuable to deliberately challenge our approach by including these regions. Doing so increased our ability to observe many different types of FPs, many of which have features that are infrequent, yet certainly present, in coding exons (e.g., low depth, repeats, and complex variants). Because our algorithm required 100% of the combined FPs (clinical and GIAB, on-and off-target) to be flagged, we know that the criteria it selects will be effective on any subset of these FPs. We also ensured validity of our results by examining GIAB quality metrics in clinical target regions alone (Supplemental Figures   13-16 ). Although the FP rates in off-target regions may be higher than those observed in clinical practice, the criteria will remain applicable.
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Our study design has important limitations. We relied on the GIAB reference call sets, which are highly accurate but imperfect [17] . For example, false-negative variant clusters are known to exist in the GIAB reference call sets, which will incorrectly appear as FPs in our laboratory data. In addition, when sequencing the Coriell GIAB specimens, there can be genetic differences compared with the original DNA samples used to develop the GIAB call sets. In general, these two issues will cause our methodology to establish broader criteria than might otherwise be necessary. Such errors do not increase the risk of an FP being missed, but they do increase the number of TPs that are flagged. Given our study's objective, this is the "better" problem to have. In our study, outliers (FPs in the GIAB data with unusually high confidence in our data) were examined in detail to ensure that the results appeared correct. We did not confirm any sites in the GIAB specimens using an orthogonal assay, although studies following ours may find it valuable to do so.
A further limitation results from our focus on high confidence regions in the GIAB reference call sets. We have little data regarding our ability to flag FPs outside of the GIAB-HC regions, which are heterogeneous and present diverse issues that can increase FP rates [15] . Thus, the criteria described above may inadequately capture Our results have specific implications for the current New York state guidelines, which state that confirmation may be waived after "at least 10 positive samples per target gene" have been confirmed [4] . In our data, approximately half of all variants that whether the other variants in that gene are confidently called. In summary, our data argue against using the NY criteria for confirmation with multi-gene sequencing tests.
The ACMG guidelines for NGS recommend that laboratories have "extensive experience with NGS technology and be sufficiently aware of the pitfalls … before deciding that result confirmation with orthogonal technology can be eliminated " [3] . Our methodology provides a practical and rigorous way to follow this recommendation using a statistically significant dataset that can be readily generated by many laboratories. Of course, changes in NGS processes, whether biochemical or bioinformatic, could change the criteria for selecting variants for confirmation. Per guidelines, the process described in this manuscript would need to be repeated as part of validating any significant process change.
Our methodology does not address other roles that confirmation assays serve: e.g.,
verifying the identity of a specimen or determining the exact structure of indels and complex variants. Our framework also does not address the critical issue of how to handle conflicting results between NGS and confirmation assays. As Beck et al. [13] elegantly showed, naively assuming that a confirmation assay is always correct can introduce more errors into NGS data than confirmation fixes. Laboratories need to address these issues separately.
Our data show that confirmation assays can be limited to a small fraction of variants without any measurable effect on analytic specificity. An adequately large and diverse dataset is required to do this with confidence. Combining GIAB and clinical specimen data is a practical way to create such a data set, and the analysis of such data proved highly informative. Limiting confirmation assays in this careful manner may help reduce costs and improve turnaround time without compromising the quality of clinical genetic tests.
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